18.10

1.74% -0.32

Sarepta Therapeutics Inc (SRPT)

Overview News Price History Option Chain Financials Why SRPT Down? Discussions Forecast Stock Split

Sarepta Therapeutics Inc stock is traded at $18.10, with a volume of 1.56M. It is down -1.74% in the last 24 hours and up +0.78% over the past month. Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Previous Close:

$18.42

Open:

$18.22

24h Volume:

1.56M

Relative Volume:

0.47

Market Cap:

$1.91B

Revenue:

$2.18B

Net Income/Loss:

$-64.32M

P/E Ratio:

-18.77

EPS:

-0.9641

Net Cash Flow:

$91.18M

1W Performance:

+7.87%

1M Performance:

+0.78%

6M Performance:

+1.74%

1Y Performance:

-10.84%

1-Day Range:

$17.69

$18.26

1-Week Range:

$16.38

$18.73

52-Week Range:

$14.68

$25.32

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Name

Sarepta Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

617-274-4000

Address

215 FIRST STREET, CAMBRIDGE, MA

Employee

835

Twitter

@sarepta

Next Earnings Date

2026-08-05

Latest SEC Filings

SRPT's Discussions on Twitter

Compare SRPT vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SRPT Sarepta Therapeutics Inc	18.10	1.94B	2.18B	-64.32M	91.18M	-0.9641
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Equal Weight
Dec-09-25	Initiated	Wedbush	Outperform
Nov-05-25	Upgrade	Mizuho	Neutral → Outperform
Sep-22-25	Upgrade	BMO Capital Markets	Market Perform → Outperform
Jul-29-25	Upgrade	Barclays	Underweight → Equal Weight
Jul-29-25	Initiated	Bernstein	Mkt Perform
Jul-29-25	Reiterated	H.C. Wainwright	Sell
Jul-29-25	Upgrade	JP Morgan	Underweight → Neutral
Jul-29-25	Upgrade	Oppenheimer	Perform → Outperform
Jul-28-25	Downgrade	Barclays	Equal Weight → Underweight
Jul-25-25	Downgrade	JP Morgan	Neutral → Underweight
Jul-24-25	Initiated	Citigroup	Sell
Jul-23-25	Downgrade	BofA Securities	Neutral → Underperform
Jul-22-25	Downgrade	Barclays	Overweight → Equal Weight
Jul-21-25	Downgrade	Deutsche Bank	Buy → Hold
Jul-21-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-21-25	Downgrade	Mizuho	Outperform → Neutral
Jul-21-25	Downgrade	Needham	Hold → Underperform
Jul-21-25	Downgrade	UBS	Buy → Neutral
Jul-18-25	Downgrade	Needham	Buy → Hold
Jun-20-25	Downgrade	William Blair	Outperform → Mkt Perform
Jun-18-25	Downgrade	TD Cowen	Buy → Hold
Jun-17-25	Initiated	Wolfe Research	Peer Perform
Jun-16-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Jun-16-25	Downgrade	BofA Securities	Buy → Neutral
Jun-16-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-16-25	Downgrade	H.C. Wainwright	Neutral → Sell
Jun-16-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-16-25	Downgrade	Piper Sandler	Overweight → Neutral
Jun-06-25	Upgrade	Scotiabank	Sector Perform → Sector Outperform
May-08-25	Downgrade	Evercore ISI	Outperform → In-line
Apr-11-25	Initiated	Wells Fargo	Overweight
Apr-02-25	Upgrade	H.C. Wainwright	Sell → Neutral
Mar-31-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Feb-11-25	Initiated	Deutsche Bank	Hold
Nov-27-24	Reiterated	Needham	Buy
Nov-25-24	Initiated	H.C. Wainwright	Sell
Nov-07-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Oct-21-24	Initiated	Jefferies	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Jul-29-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jun-26-24	Downgrade	Citigroup	Buy → Neutral
May-31-24	Initiated	Piper Sandler	Overweight
May-28-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
May-14-24	Upgrade	Oppenheimer	Perform → Outperform
Jan-31-24	Initiated	BMO Capital Markets	Outperform
Dec-13-23	Resumed	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Nov-21-23	Initiated	Wedbush	Outperform
Oct-31-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-31-23	Downgrade	Oppenheimer	Outperform → Perform
Jun-23-23	Downgrade	Evercore ISI	Outperform → In-line
Apr-26-23	Initiated	SMBC Nikko	Outperform
Apr-04-23	Initiated	Citigroup	Buy
Mar-01-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-22-22	Reiterated	BTIG Research	Buy
Dec-16-22	Upgrade	UBS	Neutral → Buy
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight
Jan-05-22	Reiterated	Needham	Buy
Dec-09-21	Upgrade	Oppenheimer	Perform → Outperform
Nov-05-21	Upgrade	JP Morgan	Neutral → Overweight
Sep-15-21	Upgrade	Guggenheim	Neutral → Buy
Aug-05-21	Upgrade	JP Morgan	Underweight → Neutral
Jun-15-21	Initiated	BTIG Research	Buy
Apr-26-21	Resumed	Credit Suisse	Neutral
Jan-12-21	Downgrade	Citigroup	Buy → Neutral
Jan-11-21	Downgrade	UBS	Buy → Neutral
Jan-08-21	Downgrade	JP Morgan	Overweight → Underweight
Jan-08-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-08-21	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Initiated	Berenberg	Hold
Oct-28-20	Initiated	UBS	Buy
Aug-25-20	Initiated	Raymond James	Outperform
Aug-20-20	Downgrade	Credit Suisse	Outperform → Neutral
Mar-31-20	Initiated	Mizuho	Buy
Nov-01-19	Initiated	Guggenheim	Buy
Aug-21-19	Reiterated	Needham	Buy
Jul-09-19	Reiterated	Morgan Stanley	Overweight
Jul-01-19	Reiterated	RBC Capital Mkts	Outperform
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-11-19	Reiterated	Credit Suisse	Outperform
Oct-12-18	Initiated	Bernstein	Outperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Sep-26-18	Reiterated	RBC Capital Mkts	Outperform
Sep-14-18	Resumed	BofA/Merrill	Buy
Sep-06-18	Initiated	Credit Suisse	Outperform
Aug-01-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-21-18	Reiterated	Robert W. Baird	Outperform
Jun-20-18	Reiterated	Needham	Buy
Jun-19-18	Reiterated	H.C. Wainwright	Buy

View All

Sarepta Therapeutics Inc Stock (SRPT) Latest News

Aug 14, 2026

Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to "Hold" at Zacks Research - MarketBeat

Aug 14, 2026

Sarepta Therapeutics (SRPT) submits Form 13F showing one entry and $0 value - Stock Titan

Aug 14, 2026

Massachusetts Biotech's Flagship Gene Therapy Posts Fifth Straight Quarterly Decline as Muscular Dystrophy Data Loom - Streetwise Reports

Aug 14, 2026

Aug 13, 2026

Sarepta Therapeutics (SRPT) sees 5.05% ownership reported by AQR in 13G/A - Stock Titan

Aug 13, 2026

Bank of America Corp DE Increases Stock Position in Sarepta Therapeutics, Inc. $SRPT - MarketBeat

Aug 13, 2026

SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits

Aug 12, 2026

Assenagon Asset Management S.A. Makes New $8.16 Million Investment in Sarepta Therapeutics, Inc. $SRPT - MarketBeat

Aug 12, 2026

Aug 11, 2026

SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits

Aug 11, 2026

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits

Aug 11, 2026

Dimensional Fund Advisors LP Sells 121,412 Shares of Sarepta Therapeutics, Inc. $SRPT - MarketBeat

Aug 11, 2026

Aug 10, 2026

Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1 - The National Law Review

Aug 10, 2026